nyra health targets Europe’s €65B neurological care gap
German HealthTech startup nyra health has raised €20 million to accelerate the rollout of its AI neurotherapy platform, aiming to close a neurological care gap estimated at €65 billion across Europe. The fresh capital will be used to scale clinical deployments, enhance its AI algorithms, and expand into new markets.
AI-driven rehabilitation for stroke and cognitive disorders
nyra health develops a digital platform that supports patients with conditions such as stroke, traumatic brain injury and neurodegenerative diseases. Using adaptive digital therapeutics, the system personalises therapy sessions in real time based on each patient’s performance, cognitive profile and recovery trajectory.
The platform combines clinically validated exercises with continuous data collection, enabling clinicians to track progress remotely and adjust treatment plans. By automating parts of the assessment and rehabilitation process, nyra health aims to reduce pressure on overburdened neurology and rehabilitation services.
Scaling across clinics and home-based care
The €20 million round will support product development, regulatory work and large-scale clinical integration. The company plans to deepen collaborations with hospitals, rehabilitation centres and insurers, while also expanding its home-based therapy offering for long-term neurological conditions.
Funds will be allocated to strengthen the underlying machine learning models that power its personalised treatment plans, improve multilingual support, and build interfaces tailored to both specialists and general practitioners. This dual focus is designed to make advanced neurotherapy accessible beyond major urban hospitals.
Positioning in the fast-growing digital neurotherapy market
With neurological disorders among the leading causes of disability worldwide, demand for scalable, data-driven care is surging. nyra health is positioning itself at the intersection of HealthTech, telemedicine and AI-based diagnostics, a segment attracting growing interest from both strategic healthcare players and venture investors.
By combining clinical evidence with continuous real-world data, the startup aims to offer healthcare systems measurable improvements in patient outcomes and cost efficiency. The new funding signals strong investor confidence that AI-enabled neurotherapy can become a core component of future neurological care pathways.